April 1, 2022 Breakthrough Innovation ForumBayer set to drive breakthrough innovations in the Life SciencesRead more
March 31, 2022 Not intended for U.S. and UK MediaBayer to strengthen global Pharmaceuticals production networkRead more
SPECIALIZED PRESS March 29, 2022 Not intended for U.S. and UK – Media American College of Cardiology’s 71st Annual Scientific Session (ACC.22):Bayer to present data from cardiovascular portfolio including late-breaking presentations from FIDELITY (Kerendia™) and first Phase 2b data from PACIFIC study program for oral Factor XIa inhibitor (asundexian)Read more
SPECIALIZED PRESS March 28, 2022 Not intended for U.S. and UK MediaBayer receives approval in Japan for Kerendia™ (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetesRead more
March 22, 2022 NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPANBayer refinances 1.3 billion euro hybrid bondRead more
March 22, 2022 Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver MutationsRead more
March 16, 2022 Prestigious award from the Bayer Foundation:2021 Hansen Family Award goes to Professor Kai JohnssonRead more
SPECIALIZED PRESS March 16, 2022 Not intended for U.S. and UK MediaBayer submits application in the EU for an extension of the indication of finerenone to include early stages of chronic kidney disease associated with type 2 diabetesRead more
SPECIALIZED PRESS March 11, 2022 Not intended for U.S. and UK MediaBayer submits application for additional indication of Nubeqa™ (darolutamide) in JapanRead more
.jpg)
